American Society of Hirudotherapy

LHyal (Leech Hyaluronidase)

Hyperactive Hirudo medicinalis hyaluronate hydrolase used for HA oligosaccharide industrial production — Liao 2023 yeast-surface-display recombinant biocatalyst.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 27, 2026 · ASH Editorial · based on the books
  • Hementerin80 kDa
  • Hementin80 kDa
  • Hementin-Like Protein (HLP-1)80 kDa
  • Leech Collagenase70 kDa
  • Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
  • Leech Apyrase67 kDa
  • Calin65 kDa
  • Hyaluronidase60 kDa
  • Antithrombin III binding protein58 kDa
  • Collagenolytic Fibrinolysin55 kDa
  • LHyal (Leech Hyaluronidase)50 kDa
  • Leech Thrombospondin-Like Protein50 kDa
Molecular weight (kilodaltons) of LHyal (Leech Hyaluronidase) (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
In vitro
Drug vs leech
Recombinant (genetically expressed)

Clinical translation limit

LHyal's enzymatic activity in industrial HA oligosaccharide production does NOT establish clinical efficacy as a therapeutic agent. No FDA-approved LHyal derivative exists.

Molecular Profile

Category
ECM Enzyme
Evidence tier
Preclinical
Molecular weight
50,000 Da
Source species
Hirudo medicinalis
Discovered
2023 · Liao L et al.

Biological Targets

  • → hyaluronic acid (extracellular matrix); produces size-specific HA oligosaccharides

Key Citations

  1. Liao L et al. (2023), Eng Microbiol · PMID 39628912

External Resources

    Related ECM Enzyme Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.